The synthesis of the recently discovered angiogenesis inhibitors epoxyquinols A and B, having novel polyketide derived dimeric structures, has been accomplished from the readily available Diels-Alder adduct of cyclopentadiene and p-benzoquinone through a short, simple and flexible strategy that is diversity oriented and can be adapted to an asymmetric variant. Scheme 2. Reagents and conditions: (a) 30% H 2 O 2 , 10% Na 2 CO 3 , acetone, 0°C, 95%; (b) DBU (2.1 equiv.), 40% formalin (excess), 0°C, quant.; (c) diphenyl ether, 240°C, 5 min, 97%; (d) TBSCl, imidazole, DMAP, DCM, 0°C, 72%; (e) DIBAL-H (2 equiv.), THF, −78°C, 82%; (f) 2,2dimethoxypropane, PPTS, acetone, rt 97%; (g) i. DIBAL-H, THF, −50°C, 86%; ii. Ac 2 O, pyridine, DMAP, DCM, 0°C, quant.; iii. HF-pyridine, THF, rt 87%. Scheme 3. Reagents and conditions: (a) MnO 2 , DCM, 0°C, 84%; (b) i. Ph 3 P(CH 2 CH 3 )I, nBuLi, THF, 0°C, 50%; ii. K 2 CO 3 , MeOH, 0°C, quant.; (c) PDC, DCM, rt 81%; (d) Amberlyst 15, MeOH, rt 85%; (e) MnO 2 , DCM, 0°C-rt 1 (40%), 2 (25%).
Angiogenesis or formation of new blood vessels is a complex, multi-step, biological event and abnormalities associated with this fundamental process have been implicated in cancer, rheumatoid arthritis and many other chronic inflammatory disorders. Thus, inhibition of angiogenesis has emerged as a promising approach for many diseases particularly cancer and many compounds including natural products are being explored as leads for clinical development. 1 In this context, a report by Japanese scientists in 2002 that novel pentaketide derived dimers epoxyquinol A 1 and epoxyquinol B 2, isolated from a soil based unknown fungus, exhibit potent anti-angiogenic profiles has generated a great deal of interest. 2 An interesting aspect of this finding is that 1 and 2 differ from the known angiogenesis inhibitors in both structural features and biological activity. The complex heptacyclic structures of 1 and its diastereomeric sibling 2 were elucidated on the basis of extensive high-field NMR studies and X-ray crystal structure determination of epoxyquinol A 1. 2a It was hypothesized that biosynthetically 1 and 2 could arise through an endo-selective Diels-Alder reaction between the diastereomeric 2Hpyran monomers 3a and 3b through hetero and homo dimerization, respectively (Scheme 1). 2a Scheme 1. Biogenetic hypothesis for the natural products.
The origin of the 2H-pyran monomers 3a,b can be traced to the precursor dienal 4 through a 6p electrocyclization and further to the more robust monocyclic diol epoxide 5 (Scheme 1). Isolation of 5 from the same fungus along with 1 and 2 provides strong support to the biosynthetic proposal. 2a Interestingly, 5 bears a close structural resemblance to a family of epoxyquinol and epoxyquinone antibiotics that have aroused considerable biological and synthetic interest. 3 The unusual structure and anti-angiogenic activity profile of epoxyquinols A 1 and B 2 and the quest for new analogues of these natural products has drawn the immediate attention of the synthetic community. 4 In the past few months, enantioselective syntheses of epoxyquinols A and B by the Hayashi 4a,b and Porco 4c groups have appeared and quite understandably their endeavors have followed the proposed biosynthetic pathway. In addition, Porco et al. 4c have also reported the preparation of new diastereomers related to 1 and 2 through thermally induced equilibration and studied their inhibitory activity towards the transcription factor NF-kB. We too were enticed by the structures of epoxyquinols A and B as they surfaced 2a in the literature and wish to report here our accomplishment of the total synthesis of natural products 1 and 2 in racemic form. Our approach is also patterned along the biosynthetic pathway 2,3d,4 shown in Scheme 1 but follows a different synthetic strategy to access the key monomeric precursors 4 and 5.
The monocyclic epoxyquinol natural product 5 was identified as the initial target and its synthesis emanated from the readily available Diels-Alder adduct 6 5 of cyclopentadiene and p-benzoquinone. Base-mediated epoxidation to 7 and exhaustive hydroxymethylation in the presence of DBU delivered 8 and established two key C C bonds in a single operation and in quantitative yield. 6 Next, the epoxyquinone moiety with two strategically functionalized side arms in place was to be extracted from 8. The retro-Diels-Alder reaction of 8 proceeded smoothly in nearly quantitative yield and led to the symmetrical epoxyquinone 9 in which the two hydroxymethyl arms now needed to be differentiated (Scheme 2). One of the hydroxyl groups in 9 was selectively protected as its bulky TBS-ether 10 to facilitate regio-and stereoselective DIBAL-H reduction 7 to furnish the diol 11 (Scheme 2). 6 The diol moiety in 11 was protected as the acetonide 12. DIBAL-H reduction of 12 then led to a 2:1 mixture of epimeric alcohols which were directly acetylated and further deprotection of the TBS-group led to 13 and 14 (Scheme 2). The stereochemistry of the major hydroxy epimer 13 was secured through an X-ray crystal structure determination. 8 The allylic primary hydroxy group in 13 was oxidized with MnO 2 and the resulting aldehyde 15 was subjected to Wittig olefination to furnish a 1:1 mixture of E:Zisomers which on base hydrolysis furnished 16 and 17 (Scheme 3). 6, 9 The stereochemistry of 16, although revealed by 1 H NMR spectral analysis, was unambiguously secured through an X-ray crystal structure determination. 8 The E-isomer 16, required for elaboration to the natural products 5, 1 and 2, was subjected to PDC oxidation to deliver the dienone 18 which was found to be identical with the advanced intermediate of Hayashi et al. 4a in their synthesis of epoxyquinol A. Indeed, deprotection of the acetonide group in 18 yielded 5, which was found to be identical with the natural product. 4a,9 In a sequence similar to that described for 13, the a-epimer 14 was also transformed to epoxyquinol 5, thereby making both the diastereomers obtained from 12 serviceable, and neutralizing the lack of stereoselectivity in the DIBAL-H reduction of 12 and so enhancing the efficacy of our approach. Finally, MnO 2 oxidation of the exocyclic allylic hydroxy group in 5 was complete within minutes at 0°C and the 1 H NMR spectrum of the crude reaction mixture indicated the presence of 4 along with 3a,b in a ratio of 60:40. On allowing the reaction product to warm-up to ambient temperature ( 28°C) and leaving aside for a few hours to complete the reaction, 10 epoxyquinols A and B could be isolated along with an as yet uncharacterized but related dimeric product by column chromatography as envisaged in the biosynthetic proposal in Scheme 1. 2a,4c Our synthetic 1 and 2 were found to be spectroscopically identical 2,4c with the natural products (Scheme 3).
In summary, we have devised a simple and effective approach to the novel natural products, epoxyquinols A and B from the readily available Diels-Alder adduct of cyclopentadiene and p-benzoquinone. Our approach can be readily adapted towards the generation of structural diversity and an asymmetric version is currently under development.
